pharmaceutical manufacturing
India-Afghanistan Sign $100 Million Pharmaceutical Deal in Major Trade Shift Away From Pakistan
Nov 28, 2025 10:32 am CST
A landmark $100 million pharmaceutical agreement between India's Zydus Lifesciences and Afghanistan's Rofi's International Group signals a significant transformation in regional trade dynamics. Following the Taliban's recent ban on Pakistan trade, this deal represents Afghanistan's strategic pivot toward India for healthcare development and commercial partnerships, with plans for medicine exports and eventual domestic manufacturing in Afghanistan.
Indian Generic Medicines Unaffected by Trump's 100% Pharmaceutical Import Tariff
Sep 26, 2025 05:57 pm CST
President Trump's new 100% tariff on pharmaceutical imports targets only patented and branded products, leaving Indian generic medicines unaffected according to the Indian Pharmaceutical Alliance. With Indian companies supplying 47% of US pharmaceutical needs and generating $219 billion in healthcare savings in 2022 alone, industry leaders remain confident in their market position as they continue providing affordable medications to American consumers.
Trump's 100% Pharmaceutical Tariffs: Potential Impact on India's $8.7 Billion US Drug Exports
Sep 26, 2025 01:18 pm CST
US President Donald Trump has announced 100% tariffs on branded and patented pharmaceutical imports starting October 1, 2025, unless companies build manufacturing facilities in America. This decision could significantly impact India's pharmaceutical sector, which exported $8.7 billion in medicines to the US in FY24, representing 31% of India's total pharma exports. With Indian companies supplying 45% of US generic drugs, both nations face potential consequences including price increases and supply disruptions.
Trump Announces 100% Tariff on Pharmaceutical Imports Unless Companies Build US Manufacturing Plants
Sep 26, 2025 11:42 am CST
President Donald Trump has announced 100% tariffs on pharmaceutical imports effective October 1, 2025, with exemptions for companies actively constructing manufacturing facilities in the US. The policy could significantly impact India's pharmaceutical sector, which exports over $3.6 billion in products to the US annually. This move follows recent 50% tariffs imposed on India for purchasing Russian oil, as bilateral trade negotiations continue.